Morning Briefing

"Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday [at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle] highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) interventions," HIV Medicine Association Executive Director Andrea Weddle writes in this guest post in the Center for Global Health Policy's "Science Speaks" blog. "The FEM-PrEP study was conducted to evaluate the protective effect of a daily oral dose of emtricitabine/tenofovir disoproxil fumerate (FTC/TDF) among African women, but was halted early, in April 2011," because of "interim data analysis showing similar rates of new HIV infections among women taking daily FTC/TDF and the placebo arm," Weddle notes. Van Damme said blood monitoring did not show levels of the drug consistent with self-reported adherence rates, according to Weddle (3/6).